Brief: Paladin Labs Announces Health Canada's Filing Acceptance Of Cenobamate Tablets As An Adjunctive Therapy
08/08/2022 23:37
Aug 8 (Reuters) - Endo International PLC ENDP.O :
* PALADIN LABS ANNOUNCES HEALTH CANADA'S FILING ACCEPTANCE
OF
CENOBAMATE TABLETS AS AN ADJUNCTIVE THERAPY FOR THE MANAGEMENT
OF PARTIAL-ONSET SEIZURES IN ADULTS WITH EPILEPSY
* PALADIN LABS - DECISION FROM HEALTH CANADA AS TO WHETHER
CENOBAMATE TABLETS CAN BE MARKETED AND SOLD IN CANADA UNDER THIS
NDS IS EXPECTED MID-2023
Source text for Eikon: ID:nCNW5JNnya
Further company coverage: ENDP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes